|
Vir Biotechnology, Inc. (VIR) DCF Valuation
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Vir Biotechnology, Inc. (VIR) Bundle
Looking to assess the intrinsic value of Vir Biotechnology, Inc.? Our (VIR) DCF Calculator integrates real-world data with comprehensive customization options, enabling you to refine your forecasts and make more informed investment choices.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 67.2 | 1,087.1 | 1,580.5 | 86.2 | 74.2 | 152.3 | 312.6 | 641.5 | 1,316.7 | 2,702.3 |
| Revenue Growth, % | 0 | 1516.58 | 45.39 | -94.55 | -13.9 | 105.24 | 105.24 | 105.24 | 105.24 | 105.24 |
| EBITDA | -289.8 | 420.8 | 833.1 | -664.9 | -537.6 | -63.5 | -130.4 | -267.6 | -549.3 | -1,127.3 |
| EBITDA, % | -430.96 | 38.71 | 52.71 | -771.47 | -724.49 | -41.72 | -41.72 | -41.72 | -41.72 | -41.72 |
| Depreciation | 8.8 | 12.0 | 15.5 | 19.5 | 14.6 | 17.5 | 35.9 | 73.6 | 151.1 | 310.1 |
| Depreciation, % | 13.11 | 1.1 | 0.98021 | 22.57 | 19.62 | 11.48 | 11.48 | 11.48 | 11.48 | 11.48 |
| EBIT | -298.6 | 408.8 | 817.6 | -684.3 | -552.2 | -64.2 | -131.7 | -270.3 | -554.8 | -1,138.6 |
| EBIT, % | -444.06 | 37.6 | 51.73 | -794.04 | -744.11 | -42.13 | -42.13 | -42.13 | -42.13 | -42.13 |
| Total Cash | 736.9 | 708.1 | 2,402.0 | 1,522.4 | 990.4 | 141.7 | 290.8 | 596.8 | 1,224.9 | 2,513.9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | 773.1 | .0 | .0 | .0 | 21.7 | 44.5 | 91.2 | 187.3 | 384.4 |
| Account Receivables, % | 0 | 71.12 | 0 | 0 | 0 | 14.22 | 14.22 | 14.22 | 14.22 | 14.22 |
| Inventories | .0 | 8.6 | .0 | .0 | .0 | .2 | .5 | 1.0 | 2.1 | 4.3 |
| Inventories, % | 0 | 0.79057 | 0 | 0 | 0 | 0.15811 | 0.15811 | 0.15811 | 0.15811 | 0.15811 |
| Accounts Payable | 5.1 | 6.5 | 6.4 | 6.3 | 5.1 | 6.9 | 14.2 | 29.2 | 59.9 | 123.0 |
| Accounts Payable, % | 7.55 | 0.59987 | 0.40633 | 7.35 | 6.85 | 4.55 | 4.55 | 4.55 | 4.55 | 4.55 |
| Capital Expenditure | -6.5 | -21.8 | -68.0 | -21.6 | -7.3 | -15.5 | -31.8 | -65.3 | -134.1 | -275.2 |
| Capital Expenditure, % | -9.74 | -2.01 | -4.3 | -25.03 | -9.84 | -10.18 | -10.18 | -10.18 | -10.18 | -10.18 |
| Tax Rate, % | 0.21889 | 0.21889 | 0.21889 | 0.21889 | 0.21889 | 0.21889 | 0.21889 | 0.21889 | 0.21889 | 0.21889 |
| EBITAT | -298.7 | 393.0 | 559.1 | -670.0 | -551.0 | -59.3 | -121.7 | -249.9 | -512.8 | -1,052.6 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -291.3 | -397.1 | 1,288.2 | -672.2 | -545.0 | -77.4 | -133.5 | -273.9 | -562.2 | -1,153.9 |
| WACC, % | 6.8 | 6.78 | 6.7 | 6.79 | 6.79 | 6.77 | 6.77 | 6.77 | 6.77 | 6.77 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1,678.7 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | -1,200 | |||||||||
| Terminal Value | -43,280 | |||||||||
| Present Terminal Value | -31,188 | |||||||||
| Enterprise Value | -32,866 | |||||||||
| Net Debt | -222 | |||||||||
| Equity Value | -32,644 | |||||||||
| Diluted Shares Outstanding, MM | 136 | |||||||||
| Equity Value Per Share | -239.59 |
What You Will Get
- Real VIR Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Intrinsic value and NPV are computed in real-time.
- Scenario Analysis: Evaluate various scenarios to assess Vir Biotechnology’s future outlook.
- User-Friendly Design: Designed for professionals while remaining approachable for newcomers.
Key Features
- Comprehensive Data: Vir Biotechnology’s historical financial records and pre-filled projections.
- Customizable Inputs: Modify discount rates, tax percentages, revenue growth, and profit margins.
- Real-Time Insights: Observe Vir Biotechnology’s intrinsic value update instantly.
- Intuitive Visual Outputs: Dashboard graphs showcase valuation outcomes and essential metrics.
- Designed for Precision: A professional-grade tool for analysts, investors, and finance professionals.
How It Works
- Download the Template: Gain immediate access to the Excel-based VIR DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and additional parameters.
- Instant Calculations: The model automatically recalculates Vir Biotechnology’s intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential changes in valuation.
- Analyze and Decide: Utilize the findings to inform your investment or financial analysis.
Why Choose This Calculator for Vir Biotechnology, Inc. (VIR)?
- Designed for Experts: A sophisticated tool tailored for analysts, investors, and industry specialists.
- Accurate Data: Vir Biotechnology’s historical and projected financials are preloaded for precision.
- Flexible Scenario Analysis: Effortlessly test various forecasts and assumptions.
- Insightful Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Comprehensive instructions lead you through each step of the calculation.
Who Should Use This Product?
- Investors: Evaluate Vir Biotechnology’s valuation prior to making investment decisions.
- CFOs and Financial Analysts: Enhance efficiency in valuation procedures and assess financial forecasts.
- Startup Founders: Understand the valuation methods applied to prominent biotech firms like Vir Biotechnology.
- Consultants: Create detailed valuation reports for your clients in the biotech sector.
- Students and Educators: Utilize real-world data from Vir Biotechnology to learn and teach valuation methodologies.
What the Template Contains
- Pre-Filled Data: Contains Vir Biotechnology's historical financials and projections.
- Discounted Cash Flow Model: Editable DCF valuation model featuring automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for WACC calculation based on user-defined inputs.
- Key Financial Ratios: Assess Vir Biotechnology's profitability, efficiency, and leverage metrics.
- Customizable Inputs: Easily modify revenue growth, margins, and tax rates.
- Clear Dashboard: Visual representations and tables summarizing essential valuation outcomes.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.